[ET Net News Agency, 9 July 2024] Morgan Stanley lowered the target price for Simcere
Pharma (02096) to HKD8.5 from HKD9 and maintained the "overweight" rating.
The research house said it lifts 2024-25e adjusted EPS by 7% and 6%, respectively, while
2026 adjusted EPS falls by 3%. (rc)